本文已被:浏览 1033次 下载 501次
Received:October 10, 2018 Published Online:March 22, 2019
Received:October 10, 2018 Published Online:March 22, 2019
中文摘要: 目的 探讨应用顺铂为主化疗方案的卵巢癌患者发生急性肾损伤(AKI) 的相关危险因素。方法 回顾分析2017年5月至2018年9月在常州市第二人民医院住院,并且接受第一轮顺铂为主化疗方案的患者,共98例,根据应用顺铂后是否发生AKI,分为AKI组及非AKI组。分析两组患者临床特点的差异,对有差异的指标进行Logistic回归分析,探讨以顺铂为主化疗方案的卵巢癌患者发生AKI的独立危险因素。结果 98例患者中有19例发生AKI,发病率为19.4%,AKI组与非AKI组患者的糖尿病、服用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂(ACEI/ARB)和应用造影剂的差异有统计学意义(P<0.05)。Logistic回归分析显示ACEI/ARB(OR=4.718,95%CI:1.290~17.254,P=0.019)和造影剂的使用(OR=6.277,95%CI:1.411~27.916,P=0.016)是患者发生顺铂所致AKI的独立危险因素。结论 服用ACEI/ARB和使用造影剂是以顺铂为主化疗方案的卵巢癌患者发生AKI的独立危险因素。
Abstract:Objective To investigate the risk factors of acute renal injury (AKI) in patients with ovarian cancer who were treated with cisplatin as the main chemotherapy regimen. Methods A retrospective analysis was made of 98 patients who were hospitalized in Changzhou No.2 People′s Hospital from May 2017 to September 2018 and received the first round of cisplatin-based chemotherapy.According to whether AKI occurred after cisplatin treatment, the patients were divided into AKI group and non-AKI group.The differences of clinical characteristics between two groups were analyzed.Logistic regression analysis was carried out to explore the independent risk factors of AKI in ovarian cancer patients treated with cisplatin as the main chemotherapy regimen. Results AKI occurred in 19 of 98 patients (19.4%).There were significant differences in diabetes mellitus, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) and radiocontrast agent between AKI group and non-AKI group (P<0.05).Logistic regression analysis showed that ACEI/ARB (OR=4.718, 95%CI:1.290-17.254, P=0.019) and contrast medium (OR=6.277, 95%CI:1.411-27.916, P=0.016) were independent risk factors for cisplatin induced AKI. Conclusion Taking ACEI/ARB and using contrast agent are independent risk factors for AKI in ovarian cancer patients with cisplatin-based chemotherapy regimen.
keywords: Ovarian cancer Cisplatin Acute renal injury risk factor Angiotensin-converting enzyme inhibitor / angiotensin receptor blocker Radiocontrast agent
文章编号: 中图分类号:R 737.31 文献标志码:B
基金项目:国家自然科学基金(81670627);常州市计划生育委员会主要科技项目(ZD201501);常州科技计划(CJ20159042)
Author Name | Affiliation |
CHEN Cheng, LIU Tong-qiang, FENG Xi | Department of Nephrology, Changzhou No.2 People′s Hospital Affiliated to Nanjing Medical University, Changzhou, Jiangsu 213003, China |
Author Name | Affiliation |
CHEN Cheng, LIU Tong-qiang, FENG Xi | Department of Nephrology, Changzhou No.2 People′s Hospital Affiliated to Nanjing Medical University, Changzhou, Jiangsu 213003, China |
引用文本: